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Multiple sclerosis (MS) is a progressive T cell-mediated autoimmune demyelinating inﬂammatory dis-
ease of the central nervous system (CNS). Although it is recognized that cognitive deﬁcits represent a
manifestation of the disease, the underlying pathogenic mechanisms remain unknown. Here we provide
evidence of spatial reference memory impairments during the pre-motor phase of experimental autoim-
mune encephalomyelitis (EAE) in mice. Speciﬁcally, these cognitive deﬁcits were accompanied by down-
regulation of choline acetyltransferase (ChAT) mRNA expression on day 5 and 11 post-immunization, and
up-regulation of inﬂammatory cytokines in the hippocampus and prefrontal cortex. Moreover, a marked
increase in B1R mRNA expression occurred selectively in the hippocampus, whereas protein level was up-
regulated in both brain areas. Genetic deletion of kinin B1R attenuated cognitive deﬁcits and cholinergic
dysfunction, and blocked mRNA expression of both IL-17 and IFN-c in the prefrontal cortex, lymph node
and spleen of mice subjected to EAE. The discovery of kinin receptors, mainly B1R, as a target for control-
ling neuroinﬂammatory response, as well as the cognitive deﬁcits induced by EAE may foster the thera-
peutic exploitation of the kallikrein–kinin system (KKS), in particular for the treatment of autoimmune
disorders, such as MS, mainly during pre-symptomatic phase.
 2013 Elsevier Inc. All rights reserved.1. Introduction
Multiple sclerosis (MS), a chronic inﬂammatory and demyelin-
ating disease that affects the central nervous system (CNS) (Sospe-
dra and Martin, 2005) is considered to be an autoimmune
pathology in which autoaggressive Th1 and Th17 lymphocytes in-
duce a response against components of myelin (Goverman, 2009;
Sospedra and Martin, 2005; Steinman, 2007). Th1 and Th17 cells
are characterized by their expression of interferon-c (IFN-c) and
interleukin-17 (IL-17), respectively. Experimental autoimmune
encephalomyelitis (EAE), a CD4+ T cell-mediated disease of the
CNS, is the best known animal model of MS and can be induced
in susceptible rodents and other animals by immunization with
myelin antigens such as myelin oligodendrocytes glycoprotein
(MOG) (Steinman, 2007). White matter inﬂammation, loss of mye-lin and consequent neuronal degeneration, the pathological hall-
marks of MS and EAE, are thought to determine the disease
severity (Ffrench-Constant, 1994). Clinical symptoms in MS in-
clude a progressive decline in motor and sensory functions and
permanent disability (Steinman, 2007).
Nonetheless, recent evidence has shown that, in MS, the neuro-
nal compartment of the CNS is affected in parallel to, and even
independently of, white matter damage, which has led to a reeval-
uation of the perceived relationship between inﬂammation and
neurodegeneration in this disease (Centonze et al., 2010; Steinman,
2007). Studies using magnetic resonance imaging (MRI) revealed
that the gray matter atrophy, which occurs in cortical and deep
sub-cortical brain regions (Filippi et al., 2003), begins early in the
disease, continues as the disease progresses (Lisak, 2007) and cor-
relates with motor, sensory and visual disability (Magnano et al.,
2006). Moreover, there is few evidence indicating that about 50–
70% of MS patients experience important cognitive deﬁcits (Rao,
1995; Shi et al., 2008) which are detectable even before a deﬁnitive
diagnosis of MS is made. These cognitive and emotional symptoms
related to MS strongly affect patients’ ability to work, as well as
their quality of life (Engel et al., 2007). Although the cause of mem-
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ing speed and working memory are the most frequently detected
cognitive deﬁcits in MS (Rao et al., 1991). In addition, verbal and
spatial learning are also affected, reﬂecting hippocampal dysfunc-
tion, especially atrophy of the CA1 region (Sicotte et al., 2008). In
this regard, some reports have proposed a linkage between cholin-
ergic system, neuroinﬂammation and cognitive impairments (Field
et al., 2012; Ruan et al., 2010; Ullrich et al., 2010). Particularly,
impairment within the cholinergic system has been demonstrated
in MS (Antonelli et al., 2013). For instance, Kooi et al. (2011) re-
ported that in MS hippocampus, both activity and protein expres-
sion of choline acetyltransferase (ChAT), the acetylcholine
synthesizing enzyme, were decreased, whereas the activity and
protein expression of acetylcholinesterase (AChE), the acetylcho-
line degrading enzyme, were found to be unaltered (Kooi et al.,
2011). Moreover, cholinergic projections arise from basal forebrain
nuclei such as medial septum/vertical limb of the diagonal band to
the hippocampus and from nucleus basalis (of Meynert) to the cor-
tex (Wevers, 2011). This anatomical split of the cholinergic system
into neocortical and hippocampal divisions underlies cholinergic
modulation of working (Croxson et al., 2011) and spatial-reference
memories (Deiana et al., 2011), respectively.
The identiﬁcation of the speciﬁc cognitive deﬁcits observed be-
fore motor symptoms in MS is of high interest because they may be
useful as temporal markers of the disease, and for testing of poten-
tial therapeutic treatments even before the onset of motor impair-
ments. Moreover, drugs currently used to treat MS focus mainly on
the control of autoimmune and neuroinﬂammatory responses.
Hence, it is incumbent upon novel studies to elucidate a molecular
substrate, with the view of discovering therapeutic interventions.
In this context, we and others have previously demonstrated that
kinin receptors, mainly the B1 receptor (B1R), exert a critical role
in regulating the early development of experimental autoimmune
encephalomyelitis (EAE) progression by modulating the onset of
the immune response and affecting the functioning of astrocytes/
microglia cells (Dutra et al., 2011).
Kinins (such as bradykinin and kallidin) are the most potent
autacoids involved in inﬂammatory, vascular and pain processes,
and constitute the end-products of the so-called kallikrein–kinin
system (KKS). Kinins exert most of their biological effects by the
activation of two G-protein coupled receptors, denoted B1 and B2
receptors (Calixto et al., 2004; Marceau and Regoli, 2004). In this
regard, Wang and Wang demonstrated that injection of bradykinin
(BK), a preferential B2R agonist, is able to induce learning and
memory impairment when administered into the rat hippocampus
(Wang and Wang, 2002). Extending this idea, Prediger et al. (2008)
showed that kinins, acting via activation of B1R and B2R in the CNS,
exert a critical role in the spatial learning and memory deﬁcits in-
duced by the b-amyloid peptide (Ab) in mice (Prediger et al., 2008).
In addition, up-regulation of both kinin receptors in the brain was
related, directly or indirectly, to cognitive processes after infusion
of Ab (Viel et al., 2008). On the other hand, the linkage between
KKS and the cholinergic system is currently not fully established.
A relevant study conducted by Buccafusco and Serra (1985)
showed that the intracerebroventricular (i.c.v.) injection of BK in
conscious, freely moving rats evoked dose-related increases in
arterial pressure, and pretreatment with hemicholinium-3, which
deplete brain acetylcholine levels, produced a choline-reversible
blockade of the cardiovascular response to BK (Buccafusco and Ser-
ra, 1985). This notion has been extended further by Barnes et al.
(1998), who demonstrated that BK-induced bronchoconstrictor re-
sponse in asthmatics is dependent of cholinergic and sensory
nerves (Barnes et al., 1998). However, no consistent evidence for
the linkage between KKS and the cholinergic system during neur-
oinﬂammatory response, such as MS, has to date been
documented.Because kinin receptors are reported to be involved in the etiol-
ogy of EAE (Dutra et al., 2011; Gobel et al., 2011; Schulze-Topphoff
et al., 2009), and also directly modulate cognitive impairments in
experimental models of neurodegenerative disease, such as Alzhei-
mer’s disease (Prediger et al., 2008), and some kinin-induced ef-
fects depends of cholinergic and sensory nerve stimulation
(Abraham et al., 2006), herein we hypothesize that the KKS may
play a key role in modulating the development of cognitive impair-
ments in MS by decreasing neuroinﬂammation and mitigating cho-
linergic system dysfunction.2. Materials and methods
2.1. Experimental animals
Experiments were conducted using female C57BL/6 wild-type,
kinin B1R-knockout (B1R/), kinin B2R-knockout (B2R/) and ki-
nin B1B2R-knockout (B1B2R/) mice (6–10 weeks old). Deletion
of the entire coding sequences of the kinin receptors was achieved
according to previously described methods (Dutra et al., 2011; Pes-
quero et al., 2000). B1R/-, B2R/- and B1B2R/-deﬁcient mice on
the 129/SvJ background were backcrossed to C57BL/6 to produce
F10 offspring. Following the F10 offspring the line is 99% genetically
identical to the recipient strain (C57BL/6) and is considered con-
genic with it; therefore we maintained this linage by crossing them
with each other. The C57BL/6 animals were used as controls. The
mice were kept in groups of six to nine animals per cage, main-
tained under controlled temperature (22 ± 1 C), with a 12 h
light/dark cycle (lights on at 7:00 a.m.) and were given free access
to food and water. All procedures used in the present study fol-
lowed the Guide for the Care and Use of Laboratory Animals (NIH
publication No. 85-23) and were approved by the Animal Ethics
Committee of the Universidade Federal de Santa Catarina (CEUA-
UFSC, protocol number 23080038266/2008-43).
2.2. EAE induction
Experimental autoimmune encephalomyelitis (EAE) was in-
duced by subcutaneous (s.c.) immunization into the ﬂanks with
200 ll of an emulsion containing 200 lg MOG35–55 peptide and
500 lg Mycobacterium tuberculosis extract H37Ra in incomplete
Freund’s adjuvant oil, as previously described (Stromnes and Gov-
erman, 2006). In addition, the animals received 300 ng of Pertussis
toxin intraperitoneally (i.p.) on day 0 and day 2 post-immuniza-
tion. The animals were monitored daily and neurological impair-
ment was quantiﬁed using a clinical scale after day 1 post-
immunization (Stromnes and Goverman, 2006): 0, no signs of dis-
ease; 1, loss of tone in the tail; 2, hindlimb paresis; 3, hindlimb
paralysis; 4, tetraplegia and 5, moribund and/or death.
2.3. Behavioral tests
2.3.1. Rotarod test
In order to evaluate motor coordination, the mice were placed
on a rotarod apparatus at a ﬁxed rotational speed of 4 rpm, as pre-
viously described (Dutra et al., 2011) (Fig. 1A). The maximum time
for each trial was set at 60 s. Rotarod training was performed prior
to disease induction and consisted of three consecutive trials in
which the animals became familiar with the task. After disease
induction, the mice were repeatedly tested at different time points
until day 25 post-immunization.
2.3.2. Object location task
After seven days of disease induction, the spatial memory of
mice was assessed using the object location task (Fig. 1A). The task
Fig. 1. Spatial reference memory deﬁcits precede motor dysfunction during EAE. Animals were immunized with MOG35–55 peptide/CFA and Pertussis toxin. Experimental
design (A), motor coordination (B), clinical score (C), neurological state (D), novel object location memory (E and F) and Morris water maze (G and H) were analyzed in control
and EAE group. Motor coordination was evaluated using the rotarod apparatus over 25 days post-immunization (p.i.). Neurological severity scale scoring was performed nine
days after EAE induction; a higher score indicates greater neurological impairment up to a maximum of 10 points. The object location test was performed seven days after
immunization and the location index (%) assessed 90 min after training sessions in mice with or without EAE. The results of water maze test are expressed as latency to ﬁnd
the hidden platform during the four training trials (G) or as a delta value for Trial 1 – Trial 2 (H). Data are presented as means ± SEM (B, C, E, F, G and H) or
medians ± interquartile range (D) of 6–9 mice per group and are representative of three independent experiments. ⁄p < 0.05 versus random chance (50% of displaced object
investigations in test trial), and ⁄⁄p < 0.001 versus control group (Student’s t-test – B, C and F; and repeated measures ANOVA – G).
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posed to two identical objects, to later explore one of the objects
– replaced in a novel location – for a longer time than they explore
the non-displaced object (Assini et al., 2009), and has been used for
the evaluation of hippocampal-dependent memories (Assini et al.,
2009). The experimental apparatus used in this study was an open-
ﬁeld box (50 cm wide  50 cm deep  40 cm high) made of trans-
parent PVC, placed in a dimly lit (7 lx) and sound-isolated room.
Identical plastic rectangles (4 cm high  4.5 cm wide) were used
as objects. The mice were placed in the center of the apparatus
with two identical objects for 5 min. The objects were placed
7 cm away from the walls of the open ﬁeld. Exploration of the ob-jects was recorded using a stopwatch when mice sniffed, whisked,
or looked at the objects from no more than 1 cm away. After the
training phase, the mice were removed from the apparatus for
90 min. After this inter-trial interval, one object was moved to a
new location. The time spent by the animals exploring the objects
in new (novel) and old (familiar) locations was recorded over
5 min. All locations of the objects were counterbalanced among
the groups. In order to analyze the cognitive performance, a loca-
tion index was calculated as previously described (Assini et al.,
2009): (Tnovel  100)/(Tnovel + Tfamiliar), where Tnovel is the
time spent exploring the displaced object and Tfamiliar is the time
spent exploring the non-displaced object.
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The apparatus was made of black painted ﬁberglass
(97  60  60 cm), and the water was maintained at 23 ± 2 C. Four
distant cues (55  55 cm) were placed 30 cm above the upper edge
of the water tank. The target platform (10  10 cm), made of trans-
parent acrylic resin was submerged 1–1.5 cm beneath the water
surface. Starting points were marked on the outside of the pool
as north (N), south (S), east (E), and west (W). These were posi-
tioned with the lower edge 30 cm above the upper edge of the
water tank, and the position of a symbol marked the midpoint
on the perimeter of a quadrant (circle = NE quadrant, square = SE
quadrant, cross = SW quadrant, and diamond = NW quadrant). If a
mouse did not ﬁnd the platform during the trial period of 60 s, it
was gently guided to it. The water maze test was evaluated from
8–11 days after disease induction, and the animals were submitted
to a working memory version of the water maze using a protocol
identical to that previously described (Moreira et al., 2012). There
is compelling evidence that the prefrontal cortex plays a critical
role in this kind of memory (Faw, 2003). Speciﬁcally, we used a
protocol that consists of four training days (four trials per day),
during which the animals were placed in the tank facing the wall
and were then allowed to swim freely to the submerged platform.
The initial position in which the animal was placed in the tank was
one of the four vertices of the imaginary quadrants of the tank, and
this was varied among trials in a pseudo-random way. The animal
was allowed to remain on the platform for 30 s and was then
moved to the next initial position without leaving the tank. This
procedure was used to ensure that the animals maintained the vis-
uospatial information of the maze that was available during execu-
tion of the working memory task. On each subsequent training day,
the platform position was moved to the center of another quadrant
of the tank in a pseudo-random way. The experiments were video-
taped and the scores for latency of escape from the starting point to
the platform and swimming speed were later measured through
the ANY-maze™ video tracking system (Stoelting Co., Wood Dale
IL, USA).
2.3.4. Neurological severity score
After nine days of disease induction, mice were rated on the 10-
point neurological severity scale (NSS) (Fig. 1A), a composite
behavioral scale designed to measure the general neurological
state, as previously described (Schwarzbold et al., 2010). The mice
were assessed for the following traits: presence of paresis; inability
to walk straight; impairment of seeking behavior; absence of a per-
ceptible startle reﬂex; inability to exit a 30-cm-diameter circle;
inability to walk on 3-, 2-, and 1-cm-wide beams; and inability
to balance on a 0.7-cm-wide beam and a 0.5-cm-diameter round
beam for at least 10 s. If a mouse showed impairment in one of
these traits, a value of 1 was added to its NSS score. Higher scores
on the NSS thus indicate greater neurological impairment.
2.4. RNA extraction and real-time quantitative PCR
Total RNA from the hippocampus and prefrontal cortex (11 days
post-immunization, Fig. 1A) was extracted using the Trizol proto-
col and concentrations were determined using a NanoDrop 1100
(NanoDrop Technologies, Wilmington, DE, USA). An amount of
100 ng of total RNA was used for cDNA synthesis. Reverse tran-
scription was performed as described in the M-MLV Reverse Trans-
criptase protocol according to the manufacturer’s instructions.
cDNA was ampliﬁed in duplicate using the TaqMan Universal
PCR Master Mix Kit with speciﬁc TaqMan Gene Expression target
genes, the 30 quencher MGB and FAM-labeled probes for mouse
choline acetyltransferase (ChAT, Mm01221887_m1) and acetyl-
cholinesterase (AChE, Mm00477275_m1), interleukin-17 (IL-17,
Mm00439618_m1), interferon-gamma (IFN-c,Mm99999071_m1), kinin B1R (Mm00432059_s1) and kinin B2R
(Mm01339907_m1). GAPDH (NM_008084.2) was used as an
endogenous control for normalization. The PCR reactions were per-
formed in a 96-well Optical Reaction Plate (Applied Biosystems,
Foster City, CA, USA). The thermocycler parameters were as fol-
lows: 50 C for 2 min, 95 C for 10 min, 50 cycles of 95 C for 15 s
and 60 C for 1 min. Expression of the target genes was calibrated
against conditions found in control animals or cells (i.e. naïve or
wild-type (WT) mice).
2.5. Western blot analysis
The hippocampus and prefrontal cortex tissues were collected
ﬁve days after EAE induction and homogenized in complete radio
immunoprecipitation lysis buffer (RIPA). Equal amounts of protein
for each sample (30 lg) were loaded per lane and electrophoreti-
cally separated using 10% denaturing polyacrylamide gel electro-
phoresis (SDS–PAGE). After that, the proteins were transferred to
nitrocellulose membranes using a Mini Trans-Blot Cell System
(Bio-Rad Laboratories Inc., Hercules, CA, USA). Western blot analy-
sis was carried out using polyclonal rabbit anti-B1R (1:1000) (Alo-
mone Labs, Jerusalem, Israel) incubated overnight. After washing,
membrane was incubated with secondary antibodies conjugated
to horseradish peroxidase (1:25,000, Cell Signaling Technology,
Danvers, MA, USA). The immunocomplexes were visualized using
SuperSignal West Femto Chemiluminescent Substrate detection
system (Thermo Fischer Scientiﬁc, Rockford, IL, USA) and densito-
metric values were normalized using monoclonal mouse b-actin
antibody (1:500, Cell Signaling Technology, Danvers, MA, USA).
2.6. Drugs and reagents
Pertussis toxin, phosphate buffered saline (PBS) and incomplete
Freund’s adjuvant oil were all purchased from Sigma Chemical Co.
(St. Louis, MO, USA). The MOG35–55 peptide (MEVGWYRSPFSRVVH-
LYRNGK) was obtained from EZBiolab (Carmel, IN, USA) and the M.
tuberculosis extract H37Ra from Difco Laboratories (Detroit, MI,
USA). The primers and probes for mouse ChAT, AChE, IL-17, IFN-
c, B1R, B2R and GAPDH were purchased from Applied Biosystems
(Warrington, UK). The polyclonal rabbit anti-B1R was purchased
from Alomone Labs (Jerusalem, Israel). Other reagents used were
all of analytical grade and obtained from different commercial
sources.
2.7. Statistical analysis
Data are presented as means ± SEM. The object location task
was analyzed by one-sample t-test to determine whether the loca-
tion index was different from random chance (50%). Other statisti-
cal analyses were carried out by using a Student’s t-test or by one-
way analysis of variance (ANOVA), with repeated measures when
appropriate. Following signiﬁcant ANOVAs, multiple post-hoc
comparisons were performed using Bonferroni or Newman–Keuls
tests, depending on the experimental protocol. p-Values of less
than 0.05 (p < 0.05) were considered signiﬁcant. The statistical
analyses were performed using GraphPad Prism 4 software
(GraphPad Software Inc., San Diego, CA, USA).3. Results
3.1. Cognitive deﬁcits associated with cholinergic dysfunction precede
motor impairments in EAE
As previously described (Dutra et al., 2011), C57BL/6 mice
immunized with MOG35–55 antigen developed EAE starting 13 days
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maximum by day 20 (Fig. 1B and C). However, recent report
showed that 50–70% of MS patients have some cognitive deﬁcits
during the course of the disease (Rao, 1995; Rao et al., 1991; Shi
et al., 2008). Thus, here we assessed whether learning and memory
impairments could onset during the pre-motor phase of EAE (days
0–11 post-immunization, Fig. 1A). Firstly, we evaluated short-term
spatial memory of mice using an object location task. One week
after EAE induction, object location memory performance was sig-
niﬁcantly impaired, as no difference between the time spent
exploring displaced and non-displaced objects could be observed
(t = 1.43; p = 0.20; Fig. 1F). In contrast, the control group, treated
with saline one week before behavioral testing, explored the object
replaced in a novel location for a longer time than the non-dis-
placed object, as indicated by a signiﬁcant increase in location in-
dex in comparison to random chance (t = 9.88; p < 0.0005; Fig. 1F).
It should be noted that no innate preference for object position was
exhibited in either control (t = 0.64; p = 0.55) or EAE (t = 0.38;
p = 0.38) mice, as indicated by the similar amounts of time spent
snifﬁng both objects during the 5-min familiarization (training)
session (Fig. 1E). Moreover, at this time, the animals (regardless
of group) did not present any gross motor alterations, as assessed
by rotarod test (Fig. 1B), clinical score (Fig. 1C) and neurological
severity scores (Fig. 1D).
Next, we assessed the spatial working and reference memory of
mice over days 8–11 post-immunization using the water maze
task. The performance of the EAE-group in the water maze test
was signiﬁcantly impaired compared with control animals, as illus-
trated by the mean latency to escape to the hidden platform
(Fig. 1G). The latency to escape to the hidden platform decreased
over the training trials for both groups (main effect of repetition,Fig. 2. EAE-induced spatial reference memory deﬁcits associated with cholinergic regulat
peptide/CFA and Pertussis toxin. On days 5 and 11 post-immunization, total RNA was extr
EAE groups and processed for choline acetyltransferase (ChAT) (A, B, E and F) and acetyl
the relative amounts of mRNA. Data are presented as means ± SEM of 6–9 mice per grou
immunized control group (Student’s t-test).F(3, 174) = 11.19, p < 0.00005), however, treatment differences
were observed (main effect of EAE, F(1, 58) = 13.32, p < 0.0005).
Speciﬁcally, escape latencies signiﬁcantly differed across treat-
ments on training trials 3 and 4 (p < 0.05; Fig. 1G), indicating spa-
tial reference memory impairments. Moreover, we calculated a
delta value by subtracting the value for trial one from trial two,
as an index of working memory. As showed in Fig. 1H we observed
no differences between groups (p = 0.86), indicating that EAE
immunization did not disrupted working memory of mice. It is
worth mentioning that the learning and memory deﬁcits were
independent frommotor deﬁcits as mice from each group had sim-
ilar swimming speeds (data not shown).
There is extensive literature indicating that speciﬁc neural
structures such as the hippocampus and prefrontal cortex plays a
critical roles in different types of memory such as spatial reference
(Burgess et al., 2002) and working memory (Faw, 2003; Wang
et al., 2011), respectively. Moreover, the close relationship be-
tween the disruption of the cholinergic system and cognitive deﬁ-
cits, such as working (Croxson et al., 2011) and spatial reference
memories impairments (Deiana et al., 2011) is well established
(Van Beek and Claassen, 2011). Herein, in order to evaluate the
possible molecular mechanisms underlying cognitive deﬁcits in-
duced by EAE model, we next investigate whether the spatial ref-
erence memory impairments were also linked to down-
regulation of cholinergic basal forebrain system. Thus, we mea-
sured ChAT mRNA expression in the hippocampus and prefrontal
cortex during the motor pre-symptomatic phase of EAE. At 11 days
post-immunization, the expression of ChAT mRNA was markedly
reduced in the hippocampus (Fig. 2A) and prefrontal cortex
(Fig. 2B) of EAE mice, which might be the underlying cause of
the spatial reference deﬁcits. Accordingly to previous reports (Tuion during the pre-motor phase of disease. Animals were immunized with MOG35–55
acted from the hippocampus and prefrontal cortex of non-immunized (control) and
cholinesterase (AChE) (C and D), respectively. GAPDH mRNA was used to normalize
p and are representative of two independent experiments. ⁄⁄p < 0.001 versus non-
Fig. 3. EAE-induced up-regulation of B1R mRNA and protein levels in the hippocampus and prefrontal cortex during the pre-motor phase of disease. Animals were immunized
with MOG35–55 peptide/CFA and Pertussis toxin. On days 5 and 11 post-immunization, total mRNA was extracted from the hippocampus and prefrontal cortex of non-
immunized (control) and EAE groups. The mRNA levels of B1R (A and B) and B2R (C and D) were measured by RT-PCR, on day 11 post-EAE induction. The housekeeping gene
GAPDHmRNAwas used to normalize the relative amounts of mRNA. The protein expression levels of B1R (E and F), in the hippocampus and prefrontal cortex, was determined
by Western blot analysis on day 5 post-immunization. The level of protein was expressed as ratio of signal intensity for the target protein relative to that for b-actin, and their
values was considered arbitrary units that represented the relative values among all samples. Data are presented as means ± SEM of 6–9 mice per group and are
representative of two independent experiments. #p < 0.05 and ⁄⁄p < 0.001 versus non-immunized control group (Student’s t-test).
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responsible for acetylcholine degradation) remained unaltered in
the hippocampus and prefrontal cortex after EAE induction
(Fig. 2C and D). In another set of experiments, we investigated
whether ChAT mRNA is down-regulated in the hippocampus and
prefrontal cortex in the earlier phase of EAE. Interestingly, on the
5th day after EAE, the expression of ChAT mRNA was signiﬁcantly
reduced in the hippocampus (Fig. 2E) and prefrontal cortex
(Fig. 2F), when compared to the control group, suggesting that cho-
linergic down-regulation occur in the CNS before memory deﬁcits.3.2. B1R is over-expressed in the hippocampus during the pre-motor
phase of EAE
Recent evidence points to the involvement of the KKS in MS and
EAE models (Dos Santos et al., 2008; Dutra et al., 2011; Gobel et al.,
2011; Schulze-Topphoff et al., 2009). Thus, we next investigate
whether the spatial reference memory impairments seen here
were also linked to the up-regulation of kinin B1 and B2 receptors
in speciﬁc brain areas during the motor pre-symptomatic phase
of EAE (on day 11 post-immunization). Basal expression of B1R
(Fig. 3A and B) and B2R (Fig. 3C and D) were detected in the hippo-
campus and prefrontal cortex of non-immunized mice. On the
other hand, during pre-motor phase of EAE, levels of kinin B1R
transcript were increased a hundred-fold in the hippocampus(Fig. 3A), but not in the prefrontal cortex (Fig. 3B). Moreover, no
signiﬁcant difference in kinin B2R mRNA levels was observed be-
tween non-immunized and EAE-groups in the hippocampus and
prefrontal cortex, respectively (Fig. 3C and D). Next, we investi-
gated whether B1R protein levels was up-regulated before spatial
reference memory impairments induced by EAE. As shown in
Fig. 3, only low protein levels of B1R were detected in the non-
immunized mouse hippocampus (Fig. 3E) and prefrontal cortex
(Fig. 3F) tissues, respectively, but these values were markedly in-
creased in EAE-group at 5 days post-immunization, suggesting that
KKS may contribute to the appearance of cognitive deﬁcits induced
by EAE during pre-motor phase.3.3. Genetic deletion of kinin B1R prevents cognitive impairments and
cholinergic dysfunction in EAE
Accordingly, the genetic deletion of B1R (Fig. 4A) drastically re-
duced the clinical score of EAE and blocked the development of the
disease (Fig. 4B and C). In marked contrast, for the genetic deletion
of B2R, or in mice that lack the genes encoding both kinin B1R and
B2R (B1B2R/) no differences were found when compared to the
wild-type EAE-group (Fig. 4B and C). This indicates that B1R has a
dominant role in inﬂuencing the development of the disease, as
previously demonstrated (Dutra et al., 2011). Presently, there is
evidence indicating that kinin receptors exert a critical role in
Fig. 4. Kinin B1R deletion prevented spatial reference memory impairments during the pre-motor phase of EAE. Animals were immunized with MOG35–55 peptide/CFA and
Pertussis toxin. Experimental design (A), motor coordination (rotarod test) (B), clinical score (C) and water maze test (D and E) were analyzed in the C57BL/6 non-immunized
group, EAE group, and in B1R/ knockout, B2R/ knockout and B1B2R/ knockout mice. The motor coordination (B) and clinical score (C) were evaluated for 25 days post-
immunization (p.i.), whereas water maze test (D and E) was performed during days 8–11 p.i. (pre-motor phase of EAE). The results of water maze test are expressed as latency
to ﬁnd the hidden platform during the four training trials (D) or as the delta value for Trial 1 – Trial 2 (E). The data are presented as means ± SEM of 6–9 mice/group and are
representative of two independent experiments. #p < 0.05, ⁄p < 0.05 and ⁄⁄p < 0.001 versus EAE-control group (one-way ANOVA with Newman–Keuls post hoc test). NS = not
signiﬁcant.
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in experimental models of Alzheimer’s disease (Lemos et al., 2010;
Prediger et al., 2008; Wang and Wang, 2002). Thus, in another set
of experiments, we investigated whether the genetic deletion of ki-
nin receptors could prevent the spatial reference memory deﬁcits
induced by EAE in mice. In previous studies, we performed ade-
quate inter-strain comparisons between wild-type and B1R/,
B2R/ and B1B2R/mice, and these ﬁndings indicated that the ge-
netic deletion of both B1R and B2R did not signiﬁcantly disrupt spa-
tial learning and memory processes in mice evaluated in the water
maze task (Prediger et al., 2008). Herein we showed that genetic
deletion of B1R signiﬁcantly mitigated the spatial reference mem-ory deﬁcits of EAE mice in the water maze task, since the escape
latencies signiﬁcantly differed when compared with C57BL/6
EAE-induced group on training trials 3 and 4 (p < 0.05; Fig. 4D).
On the other hand, genetic deletion of B2R alone or both B1R and
B2R (B1B2R/) did not signiﬁcantly prevent the cognitive impair-
ments induced by EAE in mice (Fig. 4D). Moreover, one-way ANO-
VA indicated no differences between groups regarding the delta
value of Trial 1 – Trial 2 (F(4, 130) = 0,85, p = 0,49; Fig. 4E), rein-
forcing the suggestion of the absence of working memory
alterations.
We next investigated whether B1R could modulate spatial refer-
ence memory by affecting the expression levels of ChAT mRNA in
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phase of EAE. As mentioned previously, in the EAE-group, a signif-
icant decrease in the expression of ChAT mRNA was observed in
the hippocampus (Fig. 5A) and prefrontal cortex (Fig. 5B). Notably,
in B1R/ mice the down-regulation of ChAT was completely abol-
ished in the hippocampus and prefrontal cortex of mice during pre-
motor phase of EAE, respectively (Fig. 5A and B). However, the ge-
netic deletion of B2R failed to inhibit the decrease in ChAT mRNA in
the hippocampus (Fig. 5A) and prefrontal cortex (Fig. 5B) after EAE
induction. Moreover, in B1B2R/ mice this effect was only ob-
served in the hippocampus (Fig. 5A). Once again, the levels of AChE
mRNA in the hippocampus (Fig. 5C) and prefrontal cortex (Fig. 5D)
remained unchanged after EAE induction in all groups.3.4. Genetic deletion of B1R decreases the inﬂammatory response in the
cerebral and peripheral tissues during the pre-motor phase of EAE
Earlier studies have shown that autoaggressive Th17 and Th1
cells, directed against antigens that are derived from the CNS,
can induce tissue damage and neuroinﬂammation, and thus have
a crucial role during MS development (Moldovan et al., 2003;
Stromnes et al., 2008; Tzartos et al., 2008). It is now well-estab-
lished that different proinﬂammatory mediators are produced both
by inﬁltrating immune cells and by CNS-resident glial cells, mainly
astrocytes and microglial cells, orchestrating a pathogenic cascade
leading to neuroinﬂammation and axonal damage during MS (Ger-
ard and Rollins, 2001; Ibrahim et al., 2001; Lock et al., 2002). We
therefore investigated whether B1R could modulate spatial refer-
ence memory by affecting CNS inﬂammation during the pre-motor
phase of EAE. In the EAE-group, signiﬁcant increases in the expres-
sion of IL-17 (Fig. 6A and C) and IFN-c (Fig. 6B and D) mRNAs were
observed in the hippocampus and prefrontal cortex, respectively.
Surprisingly, in both B1R/ and B1B2R/ mice, the up-regulation
of IL-17 (Fig. 6C) and IFN-c (Fig. 6D) was completely abolished in
the cerebral prefrontal cortex at 11 days post-immunization, but
this effect was not observed in the hippocampus (Fig. 6A and B).Fig. 5. Kinin B1R deletion blocked ChAT mRNA levels down-regulation in the hippocamp
day, brain tissues were collected and processed for choline acetyltransferase (ChAT) and
hippocampus and prefrontal cortexes of mice in the C57BL/6 non-immunized group, the
ChAT (A and B) and AChE (C and D) were measured in the hippocampus and prefrontal
mRNA. The data are presented as means ± SEM of 6–9 mice/group and are representative
group and ⁄p < 0.05 versus EAE-control group (one-way ANOVA with Newman–Keuls poFurthermore, the deletion of B2R did not give rise to signiﬁcant de-
creases in IL-17 and IFN-c expression in either the hippocampus or
prefrontal cortex when assessed during pre-symptomatic phase of
EAE (Fig. 6A–D). In another set of experiments, we investigated
whether IL-17 and IFN-c mRNA are up-regulated in the peripheral
lymphoid tissue, such as lymph node and spleen, after EAE induc-
tion. As shown in Fig. 6(E–H), in EAE-group, a signiﬁcant up-regu-
lation of IL-17 (Fig. 6E and G) and IFN-c (Fig. 6F and H) mRNAs was
observed in the lymph node and spleen, respectively. Of great rel-
evance, genetic deletion of B1R resulted in a marked reduction of
IL-17 and IFN-cmRNA in the lymph node (Fig. 6E and F) and spleen
(Fig. 6G and H), respectively, at 11 days post-immunization, sug-
gesting that B1R modulates inﬂammatory response in the cerebral
and peripheral tissues during the pre-motor phase of EAE.4. Discussion
Recent evidence has shown that the neuronal compartment of
the CNS is affected in parallel to, and even independently of, white
matter damage in MS (Centonze et al., 2010; Steinman, 2001).
Accordingly, cognitive impairment occurs in up to 65% of people
with MS (Rao, 1995; Rao et al., 1991; Shi et al., 2008). Although
there is evidence that memory impairment among MS subjects
are a consequence of inadequate initial learning and not a function
of impaired retrieval (DeLuca et al., 1994), the majority studies re-
port that most patients have some difﬁculty in remembering infor-
mation learned in the past (Beatty et al., 1996; Brissart et al., 2012).
For instance, verbal episodic memory impairment is frequent in
patients with MS (Brissart et al., 2012; Rao et al., 1991). Episodic
memory refers to the conscious recollection of a unique past expe-
rience in terms of ‘‘what’’ happened, ‘‘where’’ and ‘‘when’’ it hap-
pened (Tulving, 1983, 2007). In this regard, herein we showed an
impaired object location memory in the EAE-induced group. The
object location task allows to measure the memory for locations,
where objects were initially explored, by presenting two equal
and familiar objects (‘‘what’’) during the test trial, with one ofus and prefrontal cortex during the pre-motor phase of EAE. At the end of the 11th
acetylcholinesterase (AChE) mRNA expression. Total RNA was extracted from the
EAE group, and B1R/, B2R/ and B1B2R/ mice on day 11 p.i. The mRNA levels of
cortex, respectively. GAPDH mRNA was used to normalize the relative amounts of
of two independent experiments. #p < 0.05 and ##p < 0.001 versus wild-type naïve
st hoc test).
Fig. 6. Genetic deletion of B1R inhibits mRNA expression of autoimmune cytokines in the cerebral and peripheral tissues during the pre-motor phase of EAE. At the end of the
11th day, hippocampus, prefrontal cortex, inguinal lymph node and spleen tissues were collected and processed for IL-17 and IFN-c mRNA expression. Total RNA was
extracted from the hippocampus, prefrontal cortex, inguinal lymph node and spleen of mice in the non-immunized group, the EAE group, B1R/, B2R/ and B1B2R/mice on
day 11 p.i. The mRNA levels of IL-17 (A, C, E and G) and IFN-c (B, D, F and H) were measured in the hippocampus, prefrontal cortex, inguinal lymph node and spleen
respectively. GAPDH mRNA was used to normalize the relative amounts of mRNA. The data are presented as means ± SEM of 6–9 mice/group and are representative of two
independent experiments. #p < 0.05 versus non-immunized group, ⁄p < 0.05 versus EAE-control group (one-way ANOVA with Newman–Keuls post hoc test).
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components of an episode experienced by animals were assessed
conjointly, it is worth mentioning that it does not make up an epi-
sodic memory test (Ennaceur, 2010), nevertheless, at least in part,
we corroborated clinical data linking episodic memory impairment
with MS. Afterwards, we showed that the performance of the EAE-
group in the Water maze task was signiﬁcantly impaired when
compared with control mice. Morris water maze performance in-
volves different components, including concept formation (learn-
ing the general rules of the task), attention, working memory,
and reference memory (Anisman and McIntyre, 2002). Our exper-
imental protocol allowed distinguishing between working and ref-
erence memories. In this regard, we presented evidence for speciﬁc
reference memory impairments in the EAE group. Particularly, ver-
bal and spatial learning are affected in MS subjects, reﬂecting hip-
pocampal dysfunction (Sicotte et al., 2008).
Accumulated evidence now suggests that in EAE and MS pathol-
ogy, T cell activation in the periphery against myelin antigens, and
their subsequent invasion of the CNS, are considered as the primum
movens of both the experimental and human diseases (Sospedra
and Martin, 2005). These T cells are capable of (1) producing
inﬂammatory cytokines that may lead to differentiation into Th1
(IFN-c and TNF-a) or Th17 cells (IL-17, IL-21 and IL-22) (McFarland
and Martin, 2007), and (2) up-regulating integrins such as VLA-4,
that have the ability to enter the subarachnoid space by crossing
the blood-cerebrospinal ﬂuid (CSF) barrier in either the choroid
plexus or the meningeal venules (Goverman, 2009; Steinman,
2007). Through the permeabilized BBB, and attracted by chemo-
kine release, other immune cells including CD8+ T cells, B cells
and monocytes/macrophages migrate into the CNS (Fletcher
et al., 2010). Moreover, inside the CNS, the T cells are re-activated
by MHC class II-expressing macrophage/microglia and dendritic
cells (DCs), such as astrocytes, which express myelin epitopes
(Goverman, 2009). Despite the low abundance of DCs in these com-
partments, experiments that limited MHC class II expression to
DCs showed that these cells were sufﬁcient to support the develop-ment of EAE (Greter et al., 2005), and that myeloid DCs within the
CNS activated naïve myelin-speciﬁc T cells, which were recruited
to the inﬂamed tissue, and facilitated their differentiation into
Th17 cells (Bailey et al., 2007).
In this context, several lines of evidence suggest that T-cell CNS
invasion might be considered as the ﬁrst step in the chain of events
leading to brain inﬂammation and the secondary neurodegenera-
tion that occurs in MS patients (Centonze et al., 2010; Steinman,
2007). However, only a limited number of studies have been de-
voted to understanding the precise mechanisms underlying the on-
set of cognitive deﬁcits in this scenario. Here, we demonstrated
that not only the white matter, but also gray matter structures
such as the hippocampus and prefrontal cortex, are inﬁltrated by
autoaggressive Th17 and Th1 cells during the early phase of EAE.
In agreement with our data, it was recently found that inﬂamma-
tory inﬁltrates in the striatum and the cortex are mainly composed
of CD3+ T cells during the pre-symptomatic and symptomatic
phases of EAE (Centonze et al., 2010; Steinman, 2007). Moreover,
a relevant study demonstrated learning and memory deﬁcits fol-
lowing recovery from motor symptoms (90 days post-immuniza-
tion) which were associated with decreases in ChAT activity and
nerve growth factor (NGF) mRNA levels in the supraspinal struc-
tures (D’Intino et al., 2005). This has been extended by Sicotte
et al. (2008), who demonstrated that MS patients and EAE mice
showed hippocampal neurodegeneration, selective decrease in
CA1 volume and loss of GABA-ergic interneurons. Nonetheless,
these cognitive deﬁcits were evaluated at a later stage of the dis-
ease. Moreover, the relationship between the cholinergic system
and cognitive impairments is well established (Field et al., 2012;
Ruan et al., 2010; Ullrich et al., 2010). For instance, modulation
of prefrontal and hippocampal function by forebrain cholinergic
systems plays a critical role in the performance of spatial memory
tasks in rodents, since both the prefrontal cortex and hippocampus
receive substantial innervation from cholinergic cell bodies located
in the basal forebrain. Indeed, loss of such cholinergic neurons has
been correlated with memory deﬁcits in a number of neurodegen-
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et al., 2002). Our data conﬁrm and largely extend these previous
data, by demonstrating that EAE induces spatial reference memory
impairments during the pre-symptomatic phase of disease, and
that this is associated with ChAT down-regulation in the hippo-
campus and prefrontal cortex.
In subsequent phases, autoaggressive T cells enter the paren-
chyma and, together with activated macrophage/microglial cells
and astrocytes, over-express pro-inﬂammatory cytokines and ni-
tric oxide (NO) that trigger demyelination, consequently activating
neighboring immune or neural cells, and attracting further inﬂam-
matory cells into the CNS (Goverman, 2009). Emerging evidence
suggests that neuroinﬂammation could be regulated by neuropep-
tides, such as kinins (Dutra et al., 2011; Prediger et al., 2008; Schu-
lze-Topphoff et al., 2009). In fact, there are, so far, several reasons
for pointing B1R kinin as a potential therapeutic approach for the
management of inﬂammatory diseases, such as MS. Initially, the
induction of B1R has been associated with the production of pro-
inﬂammatory mediators, stimulation of inﬂammatory cells, and, ﬁ-
nally, activation of several intracellular signaling pathways (Calixto
et al., 2004). Moreover, high levels of kinin components, namely
des-Arg9-bradykinin (DABK, selective agonist for B1R), bradykinin,
kallikrein-1, kallikrein-6 and low-molecular-weight kininogens
(KNGL), have been found in CNS tissue and cerebrospinal ﬂuid from
MS patients (Schulze-Topphoff et al., 2009). In addition, the B1R
has been found to be up-regulated not only in brain endothelial
cells (Prat et al., 2000), but also in the peripheral T lymphocytes
(Prat et al., 2005) of these patients. More recently, our group and
others have reported that B1R exert a critical role in regulating
the development and progression of EAE, as well as is up-regulateFig. 7. Potential mechanism by which B1R controls activation of CD4+ T cells into the CN
during EAE. CD4+ T lymphocytes are primed in the peripheral lymphoid organs by dendr
into CNS by crossing the blood–brain barrier (BBB), mainly, in the choroid plexus (2),
expressing myelin epitopes (3). Finally, reactivated T cells, astrocytes and microglial cel
demyelination (5), dead of cholinergic neurons (6), and consequently cognitive deﬁcits.
which is directly associated with a decrease in ChAT expression in the brain, and ap
autoaggressive Th17 and Th1 cells to activate and release pro-inﬂammatory cytokines in
damage and cognitive impairments. Altogether, the modulation of this receptor may rep
helper lymphocyte; DABK: des-Arg9-BK; MOG: myelin oligodendrocytes glycoprotein;
histocompatibility complex; CXCL1/KC: keratinocyte-derived chemokine, TNF-a: tum
cyclooxygenase-2; IFN-c: interferon-gamma.in MS patients (Dos Santos et al., 2008; Dutra et al., 2011; Gobel
et al., 2011; Prat et al., 2005; Schulze-Topphoff et al., 2009), sug-
gesting that B1R inhibition may offer a novel anti-inﬂammatory
strategy for the treatment of MS. Moreover, a report suggest that
BK can modulate the cholinergic system, mainly in the airways
(Barnes et al., 1998). Herein, we demonstrated that deletion of
B1R signiﬁcantly prevented spatial reference memory impair-
ments, reduction of ChAT mRNA levels in the hippocampus and
prefrontal cortex, and blocked the increase of IL-17 and IFN-c
mRNAs induced by EAE in the prefrontal cortex, lymph node and
spleen.
Although B2R is commonly classiﬁed as a mediator of acute
inﬂammatory responses, while B1R is thought to be involved in
chronic inﬂammation (Costa-Neto et al., 2008), one cannot rule
out short-term and acute effects for B1R. The induction of B1R is
associated with several processes, including: (i) production of
inﬂammatory mediators, such as IL-1b, TNF-a, IL-2, and growth
factors; (ii) stimulation of inﬂammatory cells; and (iii) activation
of several intracellular signaling pathways, including NF-jB activa-
tion (Santos et al., 1999). In addition, selective NF-jB blockers have
been shown to be able to prevent B1R up-regulation, both in vitro
(Sabourin et al., 2002) and in vivo (Passos et al., 2004). Therefore,
in cases of acute inﬂammation, over-production of pro-inﬂamma-
tory cytokines may sustain the presence of active B2R as well as
B1R. These data clearly demonstrate the relevance of different clas-
ses of proteins in the modulation of B1R up-regulation, and support
the short-term effects of B1R. We have also reported that up-regu-
lation of B1R in the hippocampus and prefrontal cortex, seems di-
rectly regulates neuroinﬂammatory responses and cognitive
impairments in the motor pre-symptomatic phase of EAE. Thus,S, leading to neuroinﬂammation, loss of cholinergic neurons and cognitive deﬁcits
itic cells (DCs) presenting myelin (MOG35–55) epitopes (1). After, CD4+ T cells enter
and within the subarachnoid space, Th17 and Th1 cells are re-activated by APCs
ls (Dutra et al., 2013) (4) secrete neuroinﬂammatory soluble mediators that trigger
Spatial reference memory impairments occur before the onset of motor symptoms,
pear to be mediated by kinin B1R. Moreover, activation of B1R could stimulate
the peripheral tissue, as well as within the CNS, consequently inducing cholinergic
resent a novel therapeutic approach for MS. APC: antigen-presenting cell; Th cell: T
B1R: kinin B1 receptor; B2R: kinin B2 receptor; TCR: T cell receptor; MHC: major
or necrosis factor-alpha; IL: interleukin; NOS2: nitric oxide synthase 2; COX-2:
100 R.C. Dutra et al. / Brain, Behavior, and Immunity 33 (2013) 90–101one could suppose that, after myelin antigen presentation to naïve
lymphocytes T CD4+, occurs B1R up-regulation, an effect that seems
associate with differentiation into Th1 and Th17 cells, which mi-
grate and accumulate within the gray/white matter structures,
leading to neuroinﬂammation and consequently the loss of cholin-
ergic neurons that is responsible for the onset of cognitive impair-
ments (see scheme proposed in Fig. 7).
Understanding of the mechanisms leading to cumulative cogni-
tive deﬁcits in patients with MS, and the further development of
effective therapeutic strategies aimed at reducing disease progres-
sion, are major goals in MS research. Therefore, the characteriza-
tion of early symptoms, plus identiﬁcation of peptides/receptors
associated with neuroinﬂammation, during the pre-symptomatic
phase of MS, could give rise to temporal markers of the disease
as well as open up fresh perspectives in the development of ther-
apeutic approaches for MS. In summary, we described that spatial
reference memory impairments occur before the onset of motor
symptoms, and these effects are directly associated with a decrease
in ChAT expression in the brain areas (hippocampus and prefrontal
cortex) involved in acetylcholine control of memory acquisition
and maintenance (Fig. 7). Our data also show that the cognitive
deﬁcits, and cholinergic down-regulation, that appear in the mice
prior to any overt motor deﬁcits are strongly mediated by kinin
receptors, mainly of the B1R subtype. Moreover, we demonstrated
that the mechanisms involved in kinin receptor-mediated cogni-
tive impairment during the pre-motor phase of EAE appear to be
primarily associated with the ability of these peptides to stimulate
autoaggressive Th17 and Th1 cell activation, proliferation and
migration to the brain (Dutra et al., 2011), release pro-inﬂamma-
tory cytokines within the CNS, and consequently induced choliner-
gic damage and cognitive impairments (Fig. 7). Therefore, the
modulation of this receptor may represent a novel therapeutic ap-
proach for the management of MS.Acknowledgments
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